SCHEMBL2177397

SCHEMBL2177397

CN(c1nncc2c1OCCO2)C1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2176989 0.65 LARS1 (0.32)
SCHEMBL2177396 0.61 CHRM4 (0.34)
SCHEMBL2177953 0.58 ALDH1A1 (0.43)
SCHEMBL19250403 0.58 JAK3 (0.40)
SCHEMBL14644330 0.51 ACHE (0.32)
SCHEMBL23576940 0.51 JAK3 (0.30)
SCHEMBL4968048 0.51 JAK3 (0.36)
SCHEMBL20353616 0.50 JAK1 (0.36)
SCHEMBL21127856 0.50 ADRA2A (0.31)
SCHEMBL5261797 0.49 ITGB2 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9682991-B2 Tricyclic compounds for use as kinase inhibitors FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2017-06-20 US disclosed
EP-2519526-B1 TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS CT NAC INVESTIGACIONES ONCOLOGICAS CNIO (ES) 2014-03-26 EP disclosed
US-20130065881-A1 Tricyclic Compounds for Use as Kinase Inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (ES) 2013-03-14 US disclosed
EP-2519526-A1 TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) 2012-11-07 EP disclosed
WO-2011080510-A1 TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2011-07-07 WO disclosed